US EditionUS pharma tariffs likely weeks away as Trump plans for Alaska, sources say
- President Donald Trump's administration's announcement of new pharmaceutical tariffs is likely weeks away, according to four official and industry sources.
- Commerce Secretary Howard Lutnick expected the review of foreign drug production's impact on national security to conclude by mid-June, but it is now delayed.
- Global pharmaceutical companies anticipate phased-in tariffs on pharmaceutical products that could rise to 250%, affecting manufacturing in the U.S.
- A White House spokesperson cautioned that reports of delays in the announcement were speculation unless confirmed, indicating uncertainty surrounding the timeline.
18 Articles
18 Articles
Concerns over rising drug costs grow as Trump threatens pharmaceutical tariffs
President Donald Trump is threatening to impose tariffs on pharmaceutical imports, saying they would start small but could increase by up to 250%, a move critics say would be a major blow, especially for cancer patients.Mariana Socal, an associate professor of health policy and management at Johns Hopkins University, said 30% of cancer patients already do not fill their prescriptions because they cant afford them.Affordability of prescription dr…
US pharma tariffs expected in weeks as Trump gears up for Alaska: Report
The Republican president said as recently as last week that his plan relies on phased-in tariffs, giving drugmakers time to increase manufacturing in the United States as he pushes to alter what he says are global trade distortions in many industries.
US pharma tariffs likely weeks away, sources say
WASHINGTON: The announcement by President Donald Trump's administration of the results of a probe into pharmaceutical imports and new sector-specific US tariffs likely remains weeks away, four official and industry sources said, later than initially promised as he focuses on other matters.
US pharma tariffs likely weeks away as Trump plans for Alaska, sources say
The announcement by President Donald Trump's administration of the results of a probe into pharmaceutical imports and new sector-specific U.S. tariffs likely remains weeks away, four official and industry sources said, later than initially promised as he focuses on other matters.
Coverage Details
Bias Distribution
- 71% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
